Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-oxo-staurosporine is a **small molecule antibiotic** originally isolated from *Streptomyces platensis*[1][3][7]. It is an oxidized analogue of staurosporine and is highly fluorescent[5]. Its mechanism of action centers on **potent inhibition of protein kinases** including protein kinase C (PKC), protein kinase A (PKA), phosphorylase kinase, epidermal growth factor receptor (EGFR), and c-Src, with nanomolar IC50 values[1][3][9][5]. 7-oxo-staurosporine interferes with the cell cycle by inducing G2/M phase arrest and exhibits cytotoxicity against various tumor cell lines (including resistant and susceptible leukemia cells) and antifungal activity against the mycelial form of certain Candida species[1][2][5]. The compound has also demonstrated Ras mislocalization activity independently of PKC inhibition[6]. As an analogue of UCN-01 and staurosporine, 7-oxo-staurosporine shows comparable antitumor activity but is mainly used in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-oxo-staurosporine.